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Abstract
Fatty acid uptake and metabolism are often dysregulated in cancer cells. Fatty acid activation is a critical step that allows these 
biomolecules to enter cellular metabolic pathways such as mitochondrial β-oxidation for ATP generation or the lipogenic 
routes that generate bioactive lipids such as the inositol phospholipids. Fatty acid activation by the addition of coenzyme A 
is catalysed by a family of enzymes called the acyl CoA synthetase ligases (ACSL). Furthermore, enhanced expression of 
particular ACSL isoforms, such as ACSL4, is a feature of some more aggressive cancers and may contribute to the oncogenic 
phenotype. This study focuses on ACSL3 and ACSL4, closely related structural homologues that preferentially activate 
palmitate and arachidonate fatty acids, respectively. In this study, immunohistochemical screening of multiple soft tissue 
tumour arrays revealed that ACSL3 and ACSL4 were highly, but differentially, expressed in a subset of leiomyosarcomas, 
fibrosarcomas and rhabdomyosarcomas, with consistent cytoplasmic and granular stainings of tumour cells. The intracellular 
localisations of endogenously expressed ACSL3 and ACSL4 were further investigated by detailed subcellular fractionation 
analyses of HT1080 fibrosarcoma and MCF-7 breast cancer cells. ACSL3 distribution closely overlapped with proteins 
involved in trafficking from the trans-Golgi network and endosomes. In contrast, the ACSL4 localisation pattern more closely 
followed that of calnexin which is an  endoplasmic reticulum resident chaperone. Confocal immunofluorescence imaging of 
MCF-7 cells confirmed the intracellular localisations of both enzymes. These observations reveal new information regarding 
the compartmentation of fatty acid metabolism in cancer cells.
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Abbreviations
ACSL  Long chain fatty acyl CoA synthetase
EGFR  Epidermal growth factor receptor
HMGCR  HMG CoA reductase
HRP  Horse radish peroxidase
MAM  Mitochondrial-associated membrane
PI4KIIα  Phosphatidylinositol 4-kinase type IIα
PNS  Post-nuclear supernatant
SDS  Sodium-dodecyl-sulphate
TGN  Trans-Golgi network
Introduction
Altered cellular energetics is a recently proposed hallmark of 
cancer [1]. In this context, upregulated lipid metabolism is 
one of the most striking metabolic changes observed in many 
tumour cells [2]. This metabolic reprogramming can involve 
an increased uptake of dietary-derived fatty acids from the 
circulation; increased de novo lipogenesis to provide mem-
brane constituents and signalling lipids; and ATP generation 
through β-oxidation of fatty acids in the mitochondria [2]. 
Central to all these upregulated lipid-dependent events are 
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the long chain fatty acyl CoA synthetase (ACSL) enzymes 
which activate fatty acids intracellularly in a reaction requir-
ing Co-enzyme A and ATP to produce fatty acyl CoA [3, 4]. 
ACSL-dependent fatty acid activation is an essential prereq-
uisite for entry of these lipid molecules into the metabolic 
pathways that sustain cell proliferation and movement. The 
ACSL enzymes preferentially, although not exclusively, 
activate subsets of fatty acids based on their particular acyl 
chain length and degree of saturation. In this project, we 
focus on ACSL3 and ACSL4, which are closely related 
structural homologues. Both of these enzymes can activate 
arachidonate—an ω-6 polyunsaturated fatty acid but they 
differ in their overall substrate specificities, for example, 
ACSL3 more effectively utilises saturated fatty acids such 
as palmitate, laurate and myristate [3].
ACSL3 and ACSL4 also differ in terms of their subcel-
lular distributions and organelle associations. There are 
some reports revealing that ACSL4 is enriched at special-
ised sub-regions of the endoplasmic reticulum that forms 
tight physical contact with mitochondria [5, 6]. These sub-
domains have been termed mitochondrial-associated mem-
brane (MAM) domains and are important for intracellular 
lipid anabolism and  Ca2+ homeostasis (reviewed in [7, 8]). 
However, an ACSL4 MAM localisation has not been found 
in every cell type, and there is strong evidence that this iso-
form can localise to other organelles including endosomes 
[9], the secretory pathway [10], peroxisomes [6] and at the 
plasma membrane [11]. The structural determinants under-
lying ACSL4 targeting to different membranes are not yet 
known, but it has been suggested that for the neuronal-spe-
cific splice variant, a putative N-terminal small hydropho-
bic region could function as integral transmembrane anchor 
[11]. For ACSL3, there is also some disagreement in the 
literature regarding its steady-state subcellular localisations. 
Several reports have demonstrated that in cells with a high 
capacity for lipid storage such as hepatocytes, a pool of 
ACSL3 can be detected at the endoplasmic reticulum and 
on lipid droplets [12–14]. Moreover, structural modelling 
and mutation studies indicate that an N-terminal hydropho-
bic, hairpin structure is required both for ACSL3 catalytic 
activity and its association with the cytoplasmic face of 
the endoplasmic reticulum [14]. There are, however, also 
reports that ACSL3 is required for post-Golgi trafficking to 
the plasma membrane [10] and that it is principally targeted 
to the trans-Golgi network (TGN) [15]—at least in some cell 
types. Therefore, in order to understand more completely 
how fatty acid metabolism is compartmentalised in cancer 
cells, it is first necessary to determine the organelle-asso-
ciation patterns for endogenously ACSL3 and ACSL4 in 
different cancer subtypes and cell lines.
In addition to their key gatekeeper roles in fatty acid 
metabolism in normal tissues, ACSL3 and ACSL4 expres-
sion levels are frequently altered in cancer, and this is 
sometimes associated with a more aggressive metastatic 
phenotype and a poor prognosis [16–18]. Upregulated 
ACSL3-dependent fatty acid metabolism, and in particular 
augmented β-oxidation of ACSL3-derived lipid products, 
has recently been identified as a key determinant underlying 
the oncogenicity of lung tumour cells with a mutant KRAS 
driver mutation [19, 20]. In other recent studies, ACSL4 has 
been identified in non-biased screens as an enzyme required 
for ferroptosis [20, 21]—a particular form of iron-dependent 
cell death that can be triggered by cell death-inducing phos-
pholipid oxidation [22]. ACSL4 can supply arachidonyl-
CoA and adrenic-CoA for incorporation into phosphatidy-
lethanolamine and to a lesser degree phosphatidylinositol, 
and thus, these downstream ACSL4 product species can 
therefore be viewed as pro-ferroptotic lipid molecules [23]. 
Given the emerging importance of ACSL3 and ACSL4 in 
cancer, we describe here a series of subcellular fractiona-
tion experiments aimed at elucidating and comparing the 
subcellular distributions of these enzymes in cancer cells. 
We chose to work on the HT1080 cell line since we are inter-
ested in the subcellular organisation of phosphatidylinositol 
metabolism in these cells and in particular, the intracellular 
targeting of phosphatidylinositol 4-kinases. In light of recent 
demonstrations that ACSL4 may be involved in channelling 
specific pools of acyl chains to inositol phospholipids and 
given that ACSL3 could potentially also be important in this 
regard, we sought to establish the subcellular distributions of 
these fatty acid-activating enzymes relative to key enzymes 
involved in inositol phospholipid metabolism and signal-
ling. In addition, very little is known about the endogenous 
intracellular localisations of these ACSL isoforms in non-
hepatic cells and in cancer cells generally,  thus addressing 
this knowledge gap that was another motivation for under-
taking this study. Given that ACSL4 has been found neces-
sary for ferroptosis in breast cancer cells, we also report our 
findings regarding the subcellular targeting of endogenously 
expressed ACSL3 and ACSL4 in MCF7 breast cancer cells.
Materials and methods
Materials
The HT1080 cell line which was a gift from Prof Berditch-
evski, University of Birmingham, UK. MCF7 breast can-
cer cells were purchased from ECACC (Salisbury, UK). 
Anti-ACSL4 (#sc-365230) used for western blotting sub-
cellular fractions from HT1080 cells and in imaging con-
focal immunofluorescence studies was purchased from 
Santa Cruz Ltd (Wembley, UK). Anti-ACSL4 antibodies 
used in western blot experiments for MCF-7 subcellular 
fractions were purchased from Invitrogen (#PA5-27137) 
(Paisley, UK) and GeneTex (#GTX100260) (Wembley, 
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UK). Anti-Rab11 (#71-5300) was also purchased from 
Invitrogen (Paisley, UK). Anti-ACSL4 used in immuno-
histochemistry experiments was purchased from Protein-
tech Europe (Manchester, UK). Separate antibodies raised 
against either the C- or N-terminus of ACSL3 (#R3279-2 
and #R3279-1, respectively) for use in western blots 
were obtained from Abiocode (Agoura Hills, California, 
USA). Anti-calnexin (#ADI-SPA-860) was from Enzo 
biosciences (Exeter, UK), Anti-GM130 (#2296), Anti-
syntaxin 6 (#610636), anti-EEA1 (610457), anti-caveolin 
(#610059) and anti-prenylcysteine lyase (#612048) were 
from BD Biosciences (Oxford, UK). Anti-EGFR (#2232), 
anti-VDAC (#4866) and anti-mitofusin-1 (#14739) were 
obtained from Cell Signalling Technology, Europe B.V. 
(Leiden, The Netherlands) as were anti-Akt (#9272), 
anti-PLCγ (#2822), anti-mouse HRP-tagged secondary 
(#7076) and anti-rabbit HRP-tagged secondary (#7074) 
antibodies. Anti-TIP47 (#sc-390981) was bought from 
Santa Cruz Ltd (Wembley, UK). Anti-Sigma Receptor-1 
(#HPA018002) and anti-TOMM20 (#HPA011562) were 
purchased from Atlas Antibodies (Bromma, Sweden). 
Anti-HMGCR (#ab174830) was obtained from Abcam 
(Cambridge, UK). Anti-α-1,2-mannosidase (#045K4799) 
was purchased Sigma-Aldrich (Poole, Dorset, UK). The 
anti-phosphatidylinositol 4-kinase type IIα monoclonal 
antibody was raised in house and previously described 
[24]. All multiple tissue arrays (# T242, T244 and 
SO809a) were obtained from US Biomax (Rockville, 
USA). Dulbecco’s Modified Eagle’s medium (DMEM), 
foetal bovine serum and penicillin/streptomycin were pur-
chased from Invitrogen (Paisley, UK). Protease inhibi-
tor cocktail tablets (Complete™, without EDTA) were 
from Roche Diagnostics (Burgess Hill, West Sussex, UK). 
Tween-20 detergent, skimmed milk powder, HRP-linked 
cholera toxin B subunit from Vibrio cholera and Bradford 
reagent were bought from Sigma-Aldrich (Poole, Dorset, 
UK). Sodium-dodecyl-sulphate (SDS), glycerol, bromo-
phenol blue and dithiothreitol (DTT) were from VWR 
International (Lutterworth, UK). All other reagents were 
from Sigma-Aldrich (Poole, Dorset, UK). Pre-cast crite-
rion PAGE gels and clarity-enhanced chemiluminescence 
reagents were purchased from Bio-Rad Laboratories Ltd 
(Watford, UK).
Cell culture
HT1080 and MCF-7 cells were maintained in DMEM sup-
plemented with 10% foetal calf serum, 50 i.u./ml penicil-
lin, and 50 µg/ml streptomycin. Cells were cultured on 
145 mm dishes at 37 °C in 10%  CO2.
Equilibrium sucrose density gradient fractionation 
of HT1080 and MCF‑7 cells
For each experiment, two 145-mm dishes of confluent cell 
monolayers were used. Cell culture dishes were placed on 
ice and the medium aspirated. The cell monolayers were 
quickly washed twice with ice-cold PBS pH 7.4. The PBS 
was decanted and replaced with 1 ml of ice-cold cell homog-
enisation buffer consisting of 10 mM Tris-HCl pH 7.4, 
0.25 M sucrose plus Complete™ EDTA-free protease inhibi-
tors. The cell monolayers were scraped into homogenisation 
buffer, and the cell suspension transferred to a hand-held 
loose-fitting Dounce homogeniser where the cells were dis-
rupted by 10 strokes. The homogenised cell suspension was 
then centrifuged at 1000×g for 3 min to pellet out the nuclei 
and unbroken cells. The resultant supernatant was termed 
the post-nuclear supernatant (PNS), and this was used in 
subsequent subcellular fractionation procedures.
The supernatant was adjusted to 2 ml, transferred into a 
13.2-ml ultra-clear tube (Beckman Coulter UK Ltd, High 
Wycombe UK) and layered on top of a 15–50% w/v sucrose 
gradient that was composed of 2 ml steps of 50%, 40% and 
35%, and 1 ml of each of 30, 25, 20 and 15% w/v sucrose 
solutions dissolved in Tris 10 mM, EDTA 1 mM, EGTA 
1 mM. Each layer of sucrose solution was added drop by 
drop down the side of the tube, following the meniscus as 
it rose, to prevent mixing of the layers. The tube was filled 
to within a few millimetres of the rim. Next, the tube was 
carefully placed in an SW41 Beckman swing-out rotor and 
centrifuged overnight at 150,000×g at 4 °C. Following cen-
trifugation, the gradient fractions were collected, using a 
1-ml pipette to carefully decant 12 × 1 ml fractions starting 
at the top of the sucrose gradient.
Isolation of mitochondrial‑associated membranes 
from MCF‑7 cell
Mitochondrial-associated membranes were isolated from 
MCF-7 cells using a previously published method [25] with 
some minor adjustments. A PNS was prepared from 4 to 6 
confluent 145 mm dishes of MCF-7 cells using the same 
buffer and methods as described for equilibrium sucrose 
density gradient fractionation. The PNS was then centri-
fuged at 10,200×g for 20 min at 4 °C to produce a super-
natant consisting of cytosol and microsomes, as well as a 
crude mitochondrial pellet containing mitochondria along 
with intact MAM. The supernatant from this step was col-
lected and placed on ice to be used at a later stage. The crude 
mitochondrial pellet was collected and suspended in 500 µl 
of buffer 1(10 mM Tris, pH 7.4, 1 mM EDTA, 1 mM EGTA, 
250 mM mannitol).
MAM were subsequently separated from mitochondria 
using a Percoll density gradient. Percoll buffer (10 mM Tris, 
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pH 7.4, 1 mM EDTA 1 mM EGTA, 225 mM mannitol, 30% 
v/v/ Percoll) was added to fill 2/3 of a 13.2 ml polycarbon-
ate ultracentrifuge centrifuge tube. The crude mitochondrial 
suspension was layered carefully on top of the Percoll buffer, 
so that there was a visible line between the two layers. The 
remainder of the tube was filled to within a few millimetres 
of the rim with buffer 1 and was centrifuged at 95,000×g 
for 30 min at 4 °C, in a swinging bucket rotor (SW41TI 
Beckman Coulter OptimaTM LE80-K Ultracentrifuge) with 
deceleration set to zero. Following centrifugation the MAM 
fraction was visible as a thin, white layer above the mito-
chondria and was collected. The denser mitochondria were 
recoverable from around three quarters of the way down the 
tube, and were also collected. The MAM was diluted five-
fold  in buffer 2 (10 mM Tris, pH 7.4, 1 mM EDTA, 1 mM 
EGTA, 225 mM mannitol) and centrifuged at 6200×g for 
10 min at 4 °C. The resulting supernatant was collected and 
the pellet discarded.
The MAM and the supernatant containing microsomes/
cytosol were each placed in a 12 ml polycarbonate centrifuge 
tube, with the remainder filled with buffer 1. The tubes were 
centrifuged at 100,000×g for 1 h at 4 °C. Following this, 
the MAM was visible as loose, floating white material at 
the bottom of the tube. The supernatant was removed, and 
the MAM was collected and suspended in 200 µl of homog-
enisation buffer. The microsomal pellet was also collected 
and suspended in 200 µl of homogenisation buffer, and the 
cytosolic supernatant was discarded.
The mitochondria fraction from the Percoll gradient step 
was diluted five-fold in buffer 1, and then washed three times 
by centrifugation at 10,400×g for 10 min each. After each 
spin, 500 µl of the supernatant was discarded, and replaced 
by buffer 1. After the third spin, all of the supernatant was 
discarded, and the mitochondrial pellet was collected and 
suspended in 200 µl of buffer 2.
Lipid‑raft detection with cholera toxin b subunit
A dot-blot method previously described by us was used to 
detect lipid-raft-enriched membrane fractions [26]. Equal 
volume 1 µl samples from each subcellular fraction were 
dotted onto nitrocellulose membrane and allowed to dry at 
room temperature before being probed with probed with 
horse radish peroxidase (HRP)-conjugated cholera toxin B 
subunit (1:20,000). Bound HRP-conjugated cholera toxin B 
subunit was detected using Clarity enhanced chemilumines-
cence reagents and the FluorChem M gel imaging system 
(from ProteinSimple, Oxford, UK).
Western blotting of HT1080 subcellular fractions
Aliquots from each subcellular fraction were mixed with an 
equal volume of 2 × SDS-PAGE sample buffer containing 
DTT and heated for 10 min at 80 °C on a heat block. Sam-
ples were cooled to room temperature and used imme-
diately or stored at − 20 °C. The protein content of each 
fraction was separated by polyacrylamide gel electropho-
resis on 12% pre-cast Criterion gels (Bio-Rad Laboratories 
Ltd, Watford, UK). Equal volume samples, typically 30 µl 
from each sucrose gradient fraction were analysed in each 
experiment. The separated proteins were transferred to 
PVDF membranes using the iBlot system (Thermo Fisher 
Scientific, Life Technologies Ltd, Paisley, UK) and blocked 
for 1 h at room temperature in Tris 5 mM, NaCl 137 mM, 
0.1% Tween-20 pH 7.4 buffer (TBST) containing 5% w/v 
skimmed milk powder. Antibodies were added overnight at 
4 °C and following washing in TBST the addition of second-
ary HRP-conjugated antibodies, blots were visualised using 
the Clarity enhanced chemiluminescence reagent and the 
FluorChem M gel imaging system (ProteinSimple, Oxford, 
UK) or in some cases by exposure to X-ray film.
Image and statistical analyses
Image J software (https ://image j.net/Image J) was used to 
quantify signal intensity from both western and dot blots. 
Data were analysed and plotted using GraphPad Prism 5 
software (GraphPad, San Diego, USA). For the cholera toxin 
B subunit dot-blots, the means ± SEM of triplicate determi-
nations were calculated using GraphPad Prism 5 software.
Immunohistochemistry of sarcoma multiple tissue 
arrays
Protein expression of ACSL3 and ACSL4 in tissue micro-
array sections of tumour samples was demonstrated using 
rabbit polyclonal primary antibodies raised against ACSL3 
[#R2379-1 from Abiocode (Agoura Hills, California, USA)] 
and ACSL4 [#22401-1-AP from Proteintech Europe (Man-
chester, UK)], respectively. Antibody binding was detected 
and visualised with the Novolink TM max polymer detec-
tion system kit (Novocastra, Leica Microsystems (UK) Ltd, 
Milton Keynes, UK). Sections were dewaxed in xylene and 
taken to water through graded industrial denatured alcohol. 
Antigen retrieval was achieved by microwaving at 700 W 
for 15 min in 1 L of pH 6.0 sodium citrate buffer. The slides 
were then soaked in wash buffer, TBS with 0.04% Tween-20 
for 5 min, blocked in the peroxidase blocking solution for 
5 min then washed in wash buffer for 5 min. The slides were 
blocked for non-specific binding of the post primary using 
the kit’s protein block. The primary antibody was diluted 
to 1:300 for ACSL3 and 1:250 for ACSL4 and the slides 
were incubated for 1 h at room temperature then rinsed in 
TBS wash buffer. The slides were then placed for 25 min 
in the post-primary solution, 25 min in the polymer solu-
tion and developed with 3,3′ di-amino-benzidine with a 
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5 min buffer wash between each of the steps. Slides were 
counterstained with Mayer’s Haematoxylin for 3 min. All 
sections were dehydrated in graded IDA, cleared in xylene 
and were mounted with DPX (Leica Microsystems (UK) 
Ltd, Milton Keynes, UK). The slides were observed using 
a Zeiss Axioskop 40 (Zeiss, Cambridge, UK) and images 
were captured with an Axiocam IcC5 using Zeiss Axiovi-
sion (version 4.8.2).
Confocal laser‑scanning immunofluorescence 
microscopy
Prior to staining, cells were fixed and permeabilised by treat-
ment with − 25 °C methanol for 2 min, then immunostained 
with various antibodies. When staining with anti-ACSL3 
immunostaining experiments cells were fixed in formalin 
and detergent permeabilised, as described [27]. Cell nuclei 
were counterstained with Hoechst 33342 (Thermo Fisher 
Scientific, Life Technologies Ltd, Paisley, UK) and follow-
ing this the coverslips were mounted in ProLongGold anti-
fade reagent (Thermo Fisher Scientific, Life Technologies 
Ltd, Paisley, UK). Cells were imaged as described previ-
ously [27] using a Zeiss LSM 510 Meta laser-scanning con-
focal microscope system.
Results and discussion
Profiling ACSL3 and ACSL4 expression in soft‑tissue 
tumour microarrays
As we were interested in elucidating the subcellular localisa-
tions of ACSL3 and ACSL4 in a fibrosarcoma cell line and 
since the expression levels of both enzymes are known to be 
altered in different cancers, we decided to investigate if the 
expression levels of these proteins were altered in soft-tissue 
tumours. To this end, we used isoform-specific antibodies 
and immunohistochemistry to probe a soft-tissue tumour 
microarray containing cores from 80 different clinical cases 
(Fig. 1). Using this approach, we found high or moderate-
intensity staining for ACSL3 in 4/8 fibrosarcoma samples 
on the array. Moderate- or high-intensity signals were also 
frequently observed with leiomyosarcoma (10/20 samples) 
and some rhabdomyosarcomas (5/20 samples), but there was 
a more mixed pattern of ACSL3 expression in dermatofi-
brosarcomas (Table S1). However, there was consistently 
weak staining for ACSL3 in almost all liposarcoma cores 
(18/20 samples) (Fig. 1). Compared to ACSL3, moderate- 
or high-intensity staining for ACSL4 was less frequently 
observed across all soft-tissue tumour types examined (Sup-
plementary Table 1). Notable exceptions to this trend were 
leiomyosarcomas where high or moderate ACSL4 staining 
was detected in (8/20 samples) and rhabdomyosarcomas 
(5/20 samples). It is important to note that we could not 
find any evidence for coincident regulation of ACSL3 and 
ACSL4 expression levels in these patient samples. In further 
experiments using smaller tissue microarrays for ACSL3 and 
ACSL4, we were able to readily detect staining for ACSL4 
specifically in fibrosarcoma sections (4/4), but not in other 
soft-tissue tumours or normal tissue (Table 2S). These 
results indicated that ACSL4 expression was upregulated 
Fig. 1  Immunohistochemistry reveals differential expression of 
ACSL3 and ACSL4 in sarcomas. Multiple tissues arrays were probed 
using antibodies specific for either ACSL3 or ACSL4. Representa-
tive images are shown for ACSL3 and ACSL4 immunohistochemical 
staining of matched patient samples from a and b liposarcoma, c and 
d fibrosarcoma, e and f leiomyosarcoma, and g and h rhabdomyo-
sarcoma cores on multiple tissue arrays. Examples of negative and 
weak staining are presented in panels a, b and d, and high-intensity 
staining in the remaining panels The main image in each panel ×10 
objective magnification, and each inset is ×100 objective magnifica-
tion. Cytosplamic staining can be seen in higher-magnification inset 
images in panels c, and e–h. Note that, while ACSL3 staining was 
classified as weak overall in liposarcomas, it was nevertheless pos-
sible to visualise ACSL3 staining on the perimeter of lipid droplets in 
these samples a inset
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in some fibrosarcomas. For ACSL3, we again found con-
sistently high-intensity signals for fibrosarcoma samples 
(4/4) in a third tissue microarray (Table S3). Under higher 
100x magnification, both enzymes exhibited an intracellular, 
granular and cytoplasmic staining pattern in malignant cells 
(Fig. 1). In addition, antibodies directed against ACSL3, but 
not ACSL4, clearly decorated the perimeter of lipid droplets 
in liposarcoma samples (Fig. 1a), and this result aligns with 
the previously reported lipid droplet localisation for ACSL3 
in adipogenic cells [13, 14]. In summary, these results con-
firmed that both enzymes were expressed in a subset of soft-
tissue tumours and also that they were localised to intracel-
lular membranes in tumour cells.
Equilibrium density gradient fractionation 
of HT1080 cells
To gain further insights into the intracellular localisations 
of ACSL3 and ACSL4, we performed subcellular fractiona-
tion experiments using equilibrium sucrose density gradi-
ents. Post-nuclear supernatants were prepared from HT1080 
fibrosarcoma cells on an equilibrium 15–50 w/v % sucrose 
density gradient. This technique was used as it separates out 
organelles according to their equilibrium-buoyant densities 
which are characteristic physical properties determined by 
the intrinsic protein and lipid compositions of each mem-
brane compartment. Following overnight ultracentrifuga-
tion, 12 × 1 ml subcellular fractions were collected; frac-
tions 1 and 2 represent the region of the gradient where the 
post-nuclear supernatant was loaded, and fractions 3–12 
correspond to sucrose concentrations increasing from 15 to 
50% w/v.
The distributions of different organelles were assessed 
by western blotting equal volume samples from each den-
sity gradient fraction with antibodies raised against proteins 
known to be enriched at particular subcellular compartments 
(Fig. 2). Using this approach, we found that immunoreac-
tivity for the endoplasmic reticulum chaperone protein 
calnexin—a protein which reportedly distributes between 
MAM and non-MAM endoplasmic reticulum domains [28], 
gradually increased from fractions 6 to 12, with the strong-
est signals apparent in dense fractions 11 and 12. Immu-
noreactivity for the mitochondrial outer membrane protein 
mitofusin-1 [29, 30] was found between fractions 8–12 and 
peaked in fraction 10. LAMP1 a protein which trafficks from 
the TGN to lysosomes and which is particularly enriched at 
late endosomes [31], and also the TGN/endosomal protein 
syntaxin-6 [32] both peaked in fractions 5 and 6. Blots were 
also carried out to detect the presence of the early endoso-
mal marker protein EEA1, and this protein was found in 
gradient fractions 2–4 and 7–9 corresponding to the cyto-
solic- and membrane-bound pools of this protein, respec-
tively. The position of the plasma membrane in the gradient 
was ascertained by blotting for the epidermal growth factor 
receptor (EGFR), and we found that the main signal for this 
protein was detected in fractions 7–11 but was most pro-
nounced in fractions 8–10. This immunoreactivity distribu-
tion pattern can be rationalised on the basis of the EGFR 
























Fig. 2  Equilibrium distributions of organelle marker proteins, ACSL3 
and ACSL4 in HT1080 sucrose density gradient fractions. a Equal 
volumes of all HT1080 subcellular fractions were subjected to SDS-
PAGE separation and immunoblotted for the ER marker protein cal-
nexin; the TGN-endosomal protein syntaxin-6; the late endosomal 
protein LAMP1; the plasma membrane-associated EGFR, the early 
endosome-recruited protein EEA1; the lysosomal protein prenyl-
cysteine lyase and the mitochondrial protein mitofusin-1, ACSL3 
and ACSL4, and the inositol phospholipid-dependent enzymes Akt, 
PLCγ and PI4KIIα. Data presented are representative of experiments 
repeated 3–4 times with similar results. b The relative normalised 
distributions of anti-ACSL3 and anti-ACSL4 immunoreactivities in 
the gradient fractions. Western blotting signals were quantified using 
imageJ software. Data are representitive of experiments repeated 3–4 
times with similar results
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localising to biophysically distinct domains of the plasma 
membrane [33] and also partly to endosomal fractions [27]. 
Finally, the location of lysosomes in the gradient was deter-
mined by blotting for the lysosomal membrane protein pre-
nylcysteine lyase [34], and the signal for this enzyme was 
confined to the densest fractions 11 and 12. In summary, the 
results of this western blotting characterisation confirmed 
that the gradient effectively separated out different orga-
nelles on the basis of their intrinsic equilibrium-buoyant 
densities.
Having established that different organelles and mem-
brane compartments had characteristic density separation 
profiles we next sought to determine the subcellular distri-
butions of endogenously expressed ACSL3 and ACSL4 by 
western blotting with isoform-specific antibodies (Fig. 2). 
Using this approach, we observed that ACSL3 was predomi-
nately found in the middle of the gradient between frac-
tions 4 and 6 with a peak signal detected in fraction 5 thus 
mirroring the distributions of the TGN-endosomal protein 
syntaxin-6. In addition, a minor pool of ACSL3 was detected 
in the dense fractions 11 and 12 which closely overlapped 
with immunoreactivity for the lysosomal protein prenyl-
cysteine lyase. This gradient localisation profile suggested 
that ACSL3 is a protein enriched on TGN/endosomal mem-
branes with a small amount of the protein being trafficked 
to lysosomes. By way of contrast, immunoreactivity for the 
closely related homologue ACSL4 gradually increased in 
intensity in the dense region of the gradient beginning with 
fraction 5 but reaching a broad maximum between fractions 
10 and 12. This pattern of gradient distribution closely par-
alleled that of the endoplasmic reticulum protein calnexin 
and strongly indicated that ACSL4 likewise distributed 
throughout this membrane network. Most strikingly, when 
we plotted the normalised gradient distribution profiles of 
ACSL3 and ACSL4 we found that they were very different 
which further strengthened the idea that these proteins have 
different subcellular localisations with ACSL3 targeted to 
the TGN–lysosomal pathway and ACSL4 to the endoplasmic 
reticulum (Fig. 1b).
There is a possibility that ACSL3 could supply the ara-
chidonate tails required for the signalling pool of stearoyl 
arachidonyl-containing inositol phospholipids [3]. To inves-
tigate if ACSL3 at the TGN co-distributed with proteins 
required for receptor-stimulated inositol phospholipid sig-
nalling, we blotted for the presence of Akt and PLCγ. Using 
this approach, we observed the peak immunoreactivities for 
both of these enzymes were in the buoyant region of the 
gradient and were well separated from ACSL3 (Fig. 2). By 
way of contrast, we found that the peak immunoreactivity 
for phosphatidylinositol 4-kinase type IIα (PI4KIIα) did co-
fractionate with ACSL3 in fractions 5 and 6 of the gradient. 
PI4KIIα is an enzyme which previous studies have found 
as being localised to both endosomes [35] and the TGN 
[36] and which generates an intracellular pool of phosphati-
dylinositol 4-phosphate that functions in vesicular traffick-
ing. These results are consistent with the main cellular pool 
of ACSL3 localising to membranes involved in intracellular 
TGN-endosomal trafficking.
Whereas most of the pre-existing literature on ACSL3 
localisation has reported an endoplasmic reticulum and/
or lipid droplet localisations there is one report that this 
enzyme is targeted to lipid rafts at the TGN. Lipid rafts are 
cholesterol and sphingolipid-enriched microdomains of bio-
logical membranes implicated in the intramembrane organi-
sation of signalling and trafficking pathways. To investigate 
if there was any overlap between ACSL3 and lipid-raft-
enriched membranes, we probed for the presence of these 
structures using cholera toxin B subunit which is known 
to bind gangliosides such as GM1 and to report the pres-
ence of lipid rafts (reviewed in [37]). Using this approach, 
we found that the main cholera-toxin B reactive fractions 
were located in the dense region of the gradient and not 
in the main ACSL3-enriched membrane fractions (Fig. 3). 
This indicated that ACSL3 was unlikely to be targeted to 
the TGN-endosomal membranes solely through preferential 
association with lipid-raft membrane domains.
To investigate if the localisations of both ACSL enzymes 
was solely a feature of HT1080 cells or a more general char-
acteristic of cultured cancer cell lines, we extended our work 

















Fig. 3  Dot blot showing the gradient distribution of glycosphin-
golipid-enriched lipid-raft fractions. a Equal volumes of all HT1080 
subcellular fractions were dotted on to nitrocellulose membranes and 
probed with HRP-linked cholera toxin B subunit. b The distribution 
of the Cholera toxin B binding in the sucrose density gradient. Dot 
blotting signals were quantified using imageJ software. Data are pre-
sented as mean ± SEM of triplicate determinations
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and carried out similar subcellular fractionation and co-dis-
tribution studies with the MCF7 breast cancer cell line. In 
fractionated MCF7 cells, we observed that the endogenous 
distributions of ACSL3 and ACSL4 closely mirrored our 
findings with HT1080 cells. Using two different antibodies 
raised against either the C- or N-terminus of ACSL3, we 
found that this enzyme exhibited a clear peak of immuno-
reactivity in fraction 6 with a minor pool detected in the 
high density region of the gradient (Fig. 4). Again mirror-
ing our findings with the fibrosarcoma cells, we observed 
that the main peak of ACSL3 immunoreactivity overlapped 
with TGN/endosome-targeted proteins such as PI4KIIα, 
caveolin and LAMP1, and had a different distribution profile 
and minimal overlap with markers for other compartments 
such as the plasma membrane localised protein syntaxin-4, 
the cis-Golgi and ER protein α−1, 2-mannosidase and the 
mitochondrial protein mitofusin-1. The minor ACSL3 pool 
in fractions 10 and 11 was found to co-fractionate with the 
endosomal marker EEA1 in this dense region of the gradi-
ent. These results demonstrate that ACSL3 has very similar 
intracellular membrane distribution patterns in both MCF-7 
and HT1080 cells.
Using two different antibodies raised against ACSL4, we 
observed that ACSL4 had a markedly different distribution 
profile to ACSL3 in MCF-7 cell fractions. The distribu-
tion of ACSL4 very closely correlated with the endoplas-
mic reticulum proteins calnexin and HMG CoA reductase 
(HMGCR), and partially with PDI and Sigma1R—a pro-
tein proposed to localise specifically to ER MAM domains 
(Fig. 5). The dense region of the gradient corresponding to 
fractions 11 and 12 also contained all the immunoreactiv-
ity for the mitochondrial markers VDAC and mitofusin-1 
and this could indicate that a proportion of the total cellu-
lar ACSL4 was associated with mitochondria in addition to 
MAM domains of the ER. To distinguish between these pos-
sible subcellular locations, we employed a well-established 
method to separate MAM from ER and mitochondria [25]. 
Using this experimental strategy, we were able to repro-
ducibly isolate a membrane fraction with the expected vis-
ible and physical properties of MAM (Fig. 6), and western 
Fig. 4  Equilibrium distributions 
of organelle marker proteins and 
ACSL3 in MCF-7 subcellular 
fractions. Equal volume samples 
from each MCF-7 sucrose 
gradient fraction were subjected 
to SDS-PAGE separation and 
immunoblotted for ACSL3 
using two different antibodies, 
one raised against a C-terminal 
epitope and the other against 
an N-terminal epitope of the 
enzyme. The gradient distribu-
tions of a panel of organelle 
marker proteins was similarly 
determined by immunoblotting. 
Data presented are representi-
tive of experiments repeated 
2–3 times with similar results Mitochondria  Mitofusin-1
Lysosome Prenylcysteine lyase
Lipid rafts (PM and TGN) Caveolin
Pre-Golgi, Golgi GBF-1
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blotting confirmed that this membrane fraction was well 
separated from immunoreactivity for caveolin, HMGCR 
and unexpectedly, Sigma1R. This was not anticipated since 
Sigma1R has been proposed as a MAM marker protein in 
non-hepatic cells [25]. Furthermore, only a minor fraction 
of ACSL4 was present in the isolated MAM fraction with 
the bulk of the cellular compliment found in the cytoplas-
mic fraction. In this MAM fractionation scheme, as with 
the equilibrium sucrose density gradients, the distribution of 
ACSL4 closely mirrored that of calnexin—a protein known 
to distribute between MAM and non-MAM domains of the 
ER [38]. These findings prompted us to conclude that in a 
similar way to calnexin, ACSL4 was not restricted to MAM. 
Moreover, our results do not support the idea that either 
ACSL4 or Sigma1R are useful MAM marker proteins in all 
cell types.
To gain further insights into the intracellular targeting 
of ACSL4, we used confocal laser-scanning immunofluo-
rescence microscopy and co-immunostained for ACSL4 in 
combination with the mitochondrial protein VDAC or the 
putative MAM marker Sigma1R (Fig. 7). We observed that 
ACSL4 had a cytoplasmic pattern of staining consistent with 
an endoplasmic reticulum localisation, and furthermore, 
there was no overlap between ACSL4 and VDAC. These 
results allowed us to rule out a mitochondrial localisation for 
this enzyme. We found that Sigma1R was localised to sev-
eral membrane structures including perinuclear vesicles and 
the centrosome but exhibited very little overlap with ACSL4. 
This was unexpected given previous reports that Sigma1R 
was a MAM-specific protein and indicates that this protein 
is localised to more than one organelle in MCF-7 cells.
As with ACSL4, the steady-state localisation of ACSL3 
was imaged in fixed cells by confocal laser-scanning indi-
rect immunofluorescence experiments (Fig. 8). Using this 
technique, we observed that ACSL3 was present in vesicu-
lar puncta consistent with an endosomal localisation. Fur-
thermore, in these experiments, we observed striking co-
































Fig. 5  Equilibrium distributions of organelle marker proteins and 
ACSL4 in MCF-7 density gradient fractions. a Equal volume samples 
from each MCF-7 sucrose gradient fraction were subjected to SDS-
PAGE separation and immunoblotted for ACSL4 using two differ-
ent commercially available antibodies; antibody#1 was supplied by 
GeneTex and antibody#2 from Invitrogen. The gradient distributions 
of a panel of organelle marker proteins was similarly determined by 
immunoblotting. Data presented are representitive of experiments 
repeated 2–3 times with similar results. b The normalised distribu-
tions of anti-ACSL3 and anti-ACSL4 immunoreactivties in the gradi-
ent fractions. Western blotting signals were quantified using imageJ 







Fig. 6  ACSL4 partially localises to MAM. MAM, cytoplasmic and 
mitochondrial fractions, were prepared from MCF-7 cells. Equal vol-
umes of samples from each MCF-7 fraction were subjected to SDS-
PAGE separation and immunoblotted for ACSL4, calnexin, caveolin, 
HMGCR and Sigma1R. Each panel represents the results of an exper-
iment repeated twice with similar results
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originally identified as a mannose 6-phosphate receptor and 
Rab9-binding protein [39, 40] with endosomal trafficking 
functions. The substantial co-staining with ACSL3 noted 
here suggests that both proteins are targeted to the same traf-
ficking pathway in MCF-7 cells. Interestingly, TIP47 is also 
known as PLIN3 and has been identified as a lipid droplet-
associated protein in cells specialised for fat storage such 
as adipocytes [41]. However, our results indicate that in the 
cell lines investigated herein, TIP47 and ACSL3 are highly 
enriched on TGN–endosomal membranes.
These results shed new light on the intracellular organisa-
tion of fatty acid metabolism in cancer cells and demonstrate 
that at least in the HT1080 and MCF-7 cell lines, ACSL3 
and ACSL4 have non-overlapping intracellular distributions. 
Furthermore, these results are in concordance with the con-
cept that fatty acid activation is a highly compartmental-
ised process with fatty acids species of different acyl chain 
lengths and saturation being activated at specific subcellular 
sites. In the context of the present study, this could mean 
that the main ACSL3 substrates such as palmitate are pref-
erentially activated at the TGN, while the ACSL4 substrate 
arachidonate would be activated once it is in contact with 
the extensive endoplasmic reticulum membrane. The high 
degree of overlap with calnexin indicates that the ACSL4 
product arachidonyl-CoA could be made available for energy 
release via β-oxidation in mitochondria at MAM contact 
sites. However, as the endoplasmic reticulum is an impor-
tant site for phospholipid synthesis it is also possible that 
the ACSL4 lipid product could be incorporated in the acyl 
chain components of glycerophospholipids such as phos-
phatidylinositol which are synthesised on ER membranes. 
However, the metabolic fate the acyl-CoA products poten-
tially generated by ACSL3 on TGN/endosome membranes is 
less predictable. One possibility is that the ACSL3-derived 
acyl CoAs may be directly channelled to the generation of 
lipids required for vesicular trafficking processes such as the 
inositol phospholipids. We did note a high degree of gradient 
overlap between ACSL3 and PI4KIIα which may be sugges-
tive of a link between ACSL3 and phospholipid metabolism 
on the TGN endosomal pathway, but further work is required 
to characterise the multiple metabolic steps and enzymes that 
would be required to establish a direct link between ACSL3 
activity and inositol phospholipid acyl chain composition at 
this vesicular trafficking hub. However, the Golgi is a site for 
Fig. 7  Imaging of the subcel-
lular localisation of ACSL4 in 
MCF-7 cells. MCF-7 cells were 
formalin fixed and stained with 
antibodies to a VDAC (green) 
or b Sigma1R (green). ACSL4 
(magenta) and chromatin 
counterstained with Hoechst 
(blue). Samples were imaged 
using confocal microscopy. 
Scale bars, 10 µm. (Color figure 
online)
Fig. 8  TIP47 and ACSL3 
colocalise on membranes in 
the Golgi region. Cells were 
formalin fixed and stained with 
antibodies to TIP47 (green) and 
ACSL3 (magenta), before imag-
ing using confocal microscopy. 
Cells were counterstained with 
Hoechst; scale bar, 10 µm. 
(Color figure online)
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remodelling of acyl chain composition via the Land’s cycle, 
and we speculate that the ACSL3-activated lipid products 
may feed into this pathway via AGPAT3/LPAAT3 [42] and 
that this could potentially contribute to membrane tubula-
tion and vesicle formation processes in this compartment. 
Finally, there is some evidence that the biological activity 
of ACSL3 is also determined by non-catalytic elements of 
the enzyme: recombinant, catalytically inactive ACSL3 can 
localise to lipid droplets [14]; non-catalytic ACSL3 can 
directly bind Lyn [15] and ACSL3 is also known to enhance 
the expression of lipogenic genes [43]. These observations 
in combination suggest that the biological functions of the 
ACSL enzymes cannot be completely understood solely in 
terms of their catalytic activities and that future work should 
aim to elucidate the functional importance of their distinct 
intracellular localisations.
In terms of furthering our understanding of the roles of 
ACSL enzymes in cancer, our results demonstrate that the 
expression patterns of these enzymes differ significantly in 
sarcoma samples and also that they are differentially local-
ised in cancer cells. Although further work is necessary 
to understand the ramifications of these findings, they are 
nevertheless consistent with separable isoform-specific bio-
logical and pathological functions for the ACSLs and this 
may be useful information when considering therapeutic 
strategies to specifically target either enzyme in malignant 
disease.
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